<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973488</url>
  </required_header>
  <id_info>
    <org_study_id>STUDYTPECVP20</org_study_id>
    <nct_id>NCT04973488</nct_id>
  </id_info>
  <brief_title>Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients</brief_title>
  <official_title>Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novacescu Alexandru</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Medicine and Pharmacy &quot;Victor Babes&quot; Timisoara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Medicine and Pharmacy &quot;Victor Babes&quot; Timisoara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill&#xD;
      COVID-19 patients. The aim of this study is to determine whether combining TPE with&#xD;
      convalescent plasma (CVP) transfusion early during the intensive care unit (ICU) stay,&#xD;
      improves survival among this heterogeneous population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single centre prospective, non-randomised controlled trial will be conducted in an 8 bed&#xD;
      COVID-19 ICU and will include patients with severe COVID-19 pneumonia requiring ICU&#xD;
      monitoring and therapy. 19 patients will be treated performing TPE followed by CVP&#xD;
      transfusion while for 19 patients will receive standard treatment according to hospital&#xD;
      protocols. TPE will be initiated during the first 24 hours after ICU admission, followed&#xD;
      immediately by transfusion of CVP. The primary endpoint is survival at 30 days. Secondary&#xD;
      endpoints include assessing the evolution of biomarkers, such as the partial pressure of&#xD;
      arterial oxygen (PaO2) to fractional inspired oxygen (FiO2) ratio (P/F ratio), C reactive&#xD;
      protein (CRP), lactate dehydrogenase (LDH) and ferritin at the 7-day follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2020</start_date>
  <completion_date type="Actual">January 10, 2021</completion_date>
  <primary_completion_date type="Actual">January 10, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single group, that is divided into two arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Not masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>30 day period</time_frame>
    <description>In percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial pressure of arterial oxygen (PaO2) to fractional inspired oxygen (FiO2) ratio (P/F ratio)</measure>
    <time_frame>7 day period</time_frame>
    <description>Evolution of ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive protein (CRP)</measure>
    <time_frame>7 day period</time_frame>
    <description>Evolution of value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase (LDH)</measure>
    <time_frame>7 day period</time_frame>
    <description>Evolution of value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>7 day period</time_frame>
    <description>Evolution of value</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <condition>COVID-19 Respiratory Infection</condition>
  <condition>Acute Respiratory Failure</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the treatment arm, Therapeutic plasma exchange will be conducted in the first 24 hours after being admitted into the intensive care unit, after which convalescent plasma from donors that have had COVID-19 will be transfused</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the control arm, patients will receive standard COVID-19 treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic plasma exchange</intervention_name>
    <description>The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Transfusion of convalescent plasma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  positive reverse transcriptase PCR test for COVID 19&#xD;
&#xD;
          -  All patients included were adults (&gt;18 years)&#xD;
&#xD;
          -  Acute respiratory failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  patients with suspected or confirmed pulmonary embolism&#xD;
&#xD;
          -  patients with terminal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Municipal Hospital &quot;Dr. Teodor Andrei&quot; Lugoj</name>
      <address>
        <city>Lugoj</city>
        <state>Timis</state>
        <zip>305500</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>https://covid19.who.int</url>
    <description>World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Geneva: 2021</description>
  </link>
  <link>
    <url>https://www.covid19treatmentguidelines.nih.gov/</url>
    <description>COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health</description>
  </link>
  <link>
    <url>https://doi.org/10.1016/j.cmi.2021.04.003</url>
    <description>Focosi D, Maggi F, Franchini M, et al. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donorerecipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect. 2021;27(7):987-992</description>
  </link>
  <link>
    <url>https://doi.org/10.1038/s41586-021-03631-y</url>
    <description>Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283-288</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Medicine and Pharmacy &quot;Victor Babes&quot; Timisoara</investigator_affiliation>
    <investigator_full_name>Novacescu Alexandru</investigator_full_name>
    <investigator_title>Director of trial - Supervisor</investigator_title>
  </responsible_party>
  <keyword>Therapeutic Plasma Exchange</keyword>
  <keyword>Convalescent Plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We plan on sharing treatment protocol, demographic data of the study cohort, primary outcomes, secondary outcomes, miscellaneous data, treatment scheme, statystical data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will become available at 6 months after registering the study. It will be available for 36 months</ipd_time_frame>
    <ipd_access_criteria>Data will be shared with interested researchers, contact: novacescu_alex@yahoo.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

